Boehringer Ingelheim at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Boehringer Ingelheim brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on the cell biology behind viral vector production. Topics include the adenoviral E1 requirement for efficient AAV genome replication and split-intein markers that let several genes be engineered into HEK293 suspension cells.

OrganizationESGCT 2026 Attendance
Boehringer Ingelheim
Ingelheim, Germany
boehringer-ingelheim.com
Large pharma
Family-owned pharmaceutical company whose Viral Therapeutics Center develops oncolytic viruses and other virus-based therapies.
Poster
Wed Oct 28
1:30pm–3:30pm
Adenoviral E1 is required for efficient AAV genome replication independently of viral promoter activation
Manufacturing
Poster
Wed Oct 28
1:30pm–3:30pm
Split-intein selectable markers enable efficient multi-gene engineering of HEK293 suspension cells for viral vector production
Manufacturing

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Boehringer Ingelheim

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction